How do I buy Oric Pharmaceuticals, Inc. Common Stock (ORIC) stock?

Buying Oric Pharmaceuticals, Inc. Common Stock (ORIC) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ORIC", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ORIC by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ORIC is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Oric Pharmaceuticals, Inc. Common Stock (ORIC) Stock

Q: What is the minimum investment for ORIC on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Oric Pharmaceuticals, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · ORIC

Trade ORIC

Key stats

Market cap: $932.87M
Price / Earnings ratio: -6.6x
EPS (TTM): -$1.32
Volume: Loading
52-week high: $14.68
52-week low: $7.23

Source: third-party data provider, as of November 13, 2026

Compare with ORIC

Technical indicators

RSI 14: 37.66
MACD 12/26/9: -0.94
EMA 9 of MACD: -0.87
MACD histogram: -0.07
SMA 50: $11.75; Price below SMA 50
EMA 50: $11.16; Price below EMA 50
SMA 200: $11.02; Price below SMA 200
EMA 200: $11.02; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 5 analyst ratings

Strong Sell0

Sell0

Hold0

Buy5

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

491M324M162M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-129.5M

Net income

Earnings

No data available

Source: third-party data provider

About Oric Pharmaceuticals, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees111

CEODr. Jacob M. Chacko M.B.A., M.D.

IPO DateApr 24, 2020

HeadquartersSouth San Francisco, CA

Key Executives

Name	Title	Year Born
Dr. Jacob M. Chacko M.B.A., M.D.	President, CEO & Director	1979
Dr. Richard A. Heyman Ph.D.	Founder, Independent Chairman & Member of Scientific Advisory Board	1957
Mr. Dominic G. Piscitelli CPA, M.B.A.	Chief Financial Officer	1975
Dr. Pratik S. Multani M.D., M.S.	Chief Medical Officer	1967
Dr. Charles L. Sawyers B.A., M.D., Ph.D.	Founder & Member of Scientific Advisory Board	1959
Dr. Scott W. Lowe Ph.D.	Founder & Member of Scientific Advisory Board	—
Dr. Kevin Brodbeck Ph.D.	Chief Technical Officer	—
Dr. Lori Sickels Friedman Ph.D.	Chief Scientific Officer	1965
Mr. Daniel Iazzetti	VP & Head of People	—
Dr. Edna Chow Maneval Ph.D.	Executive Vice President of Clinical Development	1961

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-21.1	+10.0
2022	-38.6	-18.1	-30.5	-49.7	-5.6	+37.8	-16.8	-9.2	-7.2	-15.2	+31.5	+45.8
2023	-5.5	-26.2	+29.5	-11.9	-3.8	+47.2	+9.0	+10.5	-34.8	+13.8	+20.2	+11.2
2024	+20.2	+10.6	-6.2	-31.7	-3.6	-19.5	+46.6	-2.3	+1.8	-6.6	+5.2	-20.6
2025	+26.2	-20.9	-27.0	+3.3	+46.7	+19.8	-1.7	+1.1	+15.6	+12.4	-6.4	-26.6
2026	+25.6	+20.5	-8.7	+32.1	-13.5	+20.6	+1.7	+22.5	+4.5	-26.2	-0.8

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Oric Pharmaceuticals, Inc. Common Stock (ORIC) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "ORIC", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ORIC by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Oric Pharmaceuticals, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Oric Pharmaceuticals, Inc. Common Stock (ORIC) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ORIC's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Oric Pharmaceuticals, Inc. Common Stock (ORIC) Stock

Key stats

Compare with ORIC

Recent news

Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained

After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright

After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright

Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade

Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade

You can still run with the stock market's bulls, but watch the exits

You can still run with the stock market's bulls, but watch the exits

The 7 Best Biotech Stocks for Personalized Medicine Investors

The 7 Best Biotech Stocks for Personalized Medicine Investors

About Oric Pharmaceuticals, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade